Suppression of AP1 Transcription Factor Function in Keratinocyte Suppresses Differentiation

Our previous study shows that inhibiting activator protein one (AP1) transcription factor function in murine epidermis, using dominant-negative c-jun (TAM67), increases cell proliferation and delays differentiation. To understand the mechanism of action, we compare TAM67 impact in mouse epidermis and in cultured normal human keratinocytes. We show that TAM67 localizes in the nucleus where it forms TAM67 homodimers that competitively interact with AP1 transcription factor DNA binding sites to reduce endogenous jun and fos factor binding. Involucrin is a marker of keratinocyte differentiation that is expressed in the suprabasal epidermis and this expression requires AP1 factor interaction at the AP1-5 site in the promoter. TAM67 interacts competitively at this site to reduce involucrin expression. TAM67 also reduces endogenous c-jun, junB and junD mRNA and protein level. Studies with c-jun promoter suggest that this is due to reduced transcription of the c-jun gene. We propose that TAM67 suppresses keratinocyte differentiation by interfering with endogenous AP1 factor binding to regulator elements in differentiation-associated target genes, and by reducing endogenous c-jun factor expression.

[1]  G. M. Wilson,et al.  Protein Kinase C (PKC) δ Suppresses Keratinocyte Proliferation by Increasing p21Cip1 Level by a KLF4 Transcription Factor-dependent Mechanism* , 2011, The Journal of Biological Chemistry.

[2]  A. Szabowski,et al.  Delayed wound healing and epidermal hyperproliferation in mice lacking JunB in the skin. , 2006, The Journal of investigative dermatology.

[3]  D. Brash,et al.  Keratinocyte apoptosis in epidermal development and disease. , 2006, The Journal of investigative dermatology.

[4]  T. Kuroki,et al.  Protein kinase C delta and eta differently regulate the expression of loricrin and Jun family proteins in human keratinocytes. , 2010, Biochemical and biophysical research communications.

[5]  E. Wagner,et al.  Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins , 2005, Nature.

[6]  N. Colburn,et al.  A dominant negative c-jun specifically blocks okadaic acid-induced skin tumor promotion. , 2002, Cancer research.

[7]  E. Wagner,et al.  Placental vascularisation requires the AP-1 component fra1. , 2000, Development.

[8]  M. Karin,et al.  AP-1 as a regulator of cell life and death , 2002, Nature Cell Biology.

[9]  E. Wagner,et al.  JunB can substitute for Jun in mouse development and cell proliferation , 2002, Nature Genetics.

[10]  R. Eckert,et al.  The human involucrin gene contains spatially distinct regulatory elements that regulate expression during early versus late epidermal differentiation , 2002, Oncogene.

[11]  C. Vinson,et al.  Activator protein 1 transcription factors are fundamental to v-rasHa-induced changes in gene expression in neoplastic keratinocytes. , 2000, Cancer research.

[12]  Y. Tao,et al.  Blockade of AP‐1 activity by dominant‐negative TAM67 can abrogate the oncogenic phenotype in latent membrane protein 1‐positive human nasopharyngeal carcinoma , 2007, Molecular carcinogenesis.

[13]  S. Murthy,et al.  Tissue-specific and differentiation-appropriate expression of the human involucrin gene in transgenic mice: an abnormal epidermal phenotype. , 1993, Differentiation; research in biological diversity.

[14]  A. Porter,et al.  Neuronal Differentiation and Protection from Nitric Oxide-Induced Apoptosis Require c-Jun-Dependent Expression of NCAM140 , 2002, Molecular and Cellular Biology.

[15]  N. Colburn,et al.  Protection against human papillomavirus type 16‐E7 oncogene‐induced tumorigenesis by in vivo expression of dominant‐negative c‐jun † , 2002, Molecular carcinogenesis.

[16]  Yong-Yeon Cho,et al.  Effects of MAP kinase inhibitors on epidermal growth factor‐induced neoplastic transformation of human keratinocytes , 2006, Molecular carcinogenesis.

[17]  R. Eckert,et al.  Protein Kinase Cδ Regulates Keratinocyte Death and Survival by Regulating Activity and Subcellular Localization of a p38δ-Extracellular Signal-Regulated Kinase 1/2 Complex , 2004, Molecular and Cellular Biology.

[18]  A. Sabichi,et al.  Dominant-negative mutants of cJun inhibit AP-1 activity through multiple mechanisms and with different potencies. , 1996, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[19]  R. Eckert,et al.  Regulation of Human Involucrin Promoter Activity by Novel Protein Kinase C Isoforms* , 2000, The Journal of Biological Chemistry.

[20]  A. Bode,et al.  Deficiency of c-Jun-NH(2)-terminal kinase-1 in mice enhances skin tumor development by 12-O-tetradecanoylphorbol-13-acetate. , 2002, Cancer research.

[21]  P. Wei,et al.  Transrepression of c-jun gene expression by the glucocorticoid receptor requires both AP-1 sites in the c-jun promoter. , 1998, Molecular endocrinology.

[22]  H. Pass,et al.  Fra-1 governs cell migration via modulation of CD44 expression in human mesotheliomas , 2007, Molecular Cancer.

[23]  N. Colburn,et al.  Expression of dominant negative c-jun inhibits ultraviolet B-induced squamous cell carcinoma number and size in an SKH-1 hairless mouse model. , 2003, Molecular cancer research : MCR.

[24]  R. Eckert,et al.  Curcumin Suppresses AP1 Transcription Factor-dependent Differentiation and Activates Apoptosis in Human Epidermal Keratinocytes* , 2007, Journal of Biological Chemistry.

[25]  R. Eckert,et al.  AP1 Factor Inactivation in the Suprabasal Epidermis Causes Increased Epidermal Hyperproliferation and Hyperkeratosis but Reduced Carcinogen-Dependent Tumor Formation , 2010, Oncogene.

[26]  P. Herrlich,et al.  ULTRAVIOLET‐RADIATION INDUCED c‐jun GENE TRANSCRIPTION: TWO AP‐1 LIKE BINDING SITES MEDIATE THE RESPONSE , 1992, Photochemistry and photobiology.

[27]  E. Zandi,et al.  AP-1 function and regulation. , 1997, Current opinion in cell biology.

[28]  A. Ishida-Yamamoto,et al.  Extracellular regulated kinase and c-Jun N-terminal kinase are activated in psoriatic involved epidermis. , 2002, Journal of dermatological science.

[29]  M. Birrer,et al.  Mechanism of action of a dominant-negative mutant of c-Jun. , 1994, Oncogene.

[30]  A. Szabowski,et al.  Function and regulation of AP-1 subunits in skin physiology and pathology , 2001, Oncogene.

[31]  R. Eckert,et al.  Regulation of involucrin expression in normal human corneal epithelial cells: a role for activator protein one. , 2004, Investigative ophthalmology & visual science.

[32]  R. Eckert,et al.  Fos-related Antigen (Fra-1), junB, and junD Activate Human Involucrin Promoter Transcription by Binding to Proximal and Distal AP1 Sites to Mediate Phorbol Ester Effects on Promoter Activity (*) , 1995, The Journal of Biological Chemistry.

[33]  P. Fisher,et al.  AP‐1 and C/EBP transcription factors contribute to mda‐7 gene promoter activity during human melanoma differentiation , 2000, Journal of cellular physiology.

[34]  D. Taub,et al.  A dominant negative mutant of jun blocking 12‐O‐tetradecanoylphorbol‐13‐acetate–induced invasion in mouse keratinocytes , 1997, Molecular carcinogenesis.

[35]  R. Eckert,et al.  Regulation of Human Involucrin Promoter Activity by a Protein Kinase C, Ras, MEKK1, MEK3, p38/RK, AP1 Signal Transduction Pathway* , 1998, The Journal of Biological Chemistry.

[36]  R. Eckert,et al.  Involucrin is a covalently crosslinked constituent of highly purified epidermal corneocytes: evidence for a common pattern of involucrin crosslinking in vivo and in vitro. , 1996, The Journal of investigative dermatology.

[37]  N. Colburn,et al.  Transgenic mice demonstrate AP-1 (activator protein-1) transactivation is required for tumor promotion. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[38]  R. Eckert,et al.  The epidermis: genes on - genes off. , 1997, The Journal of investigative dermatology.

[39]  S. Grant,et al.  Effect of 1-beta-D-arabinofuranosylcytosine on apoptosis and differentiation in human monocytic leukemia cells (U937) expressing a c-Jun dominant-negative mutant protein (TAM67). , 1996, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[40]  A. Bosio,et al.  Identification of CD70 as a diagnostic biomarker for clear cell renal cell carcinoma by gene expression profiling, real-time RT-PCR and immunohistochemistry. , 2005, European journal of cancer.

[41]  C. Kahn,et al.  Human corneal epithelial primary cultures and cell lines with extended life span: in vitro model for ocular studies. , 1993, Investigative ophthalmology & visual science.

[42]  R. Eckert,et al.  An involucrin promoter AP1 transcription factor binding site is required for expression of involucrin in the corneal epithelium in vivo. , 2005, Investigative ophthalmology & visual science.

[43]  N. Colburn,et al.  Expression of dominant negative Jun inhibits elevated AP-1 and NF-κB transactivation and suppresses anchorage independent growth of HPV immortalized human keratinocytes , 1998, Oncogene.

[44]  Qiang Shen,et al.  AP-1 blockade in breast cancer cells causes cell cycle arrest by suppressing G1 cyclin expression and reducing cyclin-dependent kinase activity , 2004, Oncogene.

[45]  Y. Shaul,et al.  The human junD gene is positively and selectively autoregulated. , 1994, DNA and cell biology.

[46]  K. Yoneda,et al.  The human loricrin gene. , 1992, The Journal of biological chemistry.

[47]  M. Nishimura,et al.  Growth inhibition of non-small cell lung cancer cells by AP-1 blockade using a cJun dominant-negative mutant , 2008, British Journal of Cancer.

[48]  P. Stambrook,et al.  Dominant negative c-jun inhibits activation of the cyclin D1 and cyclin E kinase complexes. , 2001, Molecular biology of the cell.

[49]  M. Karin,et al.  Rapid and preferential activation of the c-jun gene during the mammalian UV response , 1991, Molecular and cellular biology.

[50]  G. T. Bowden,et al.  Mechanism of action of a dominant negative c‐jun mutant in inhibiting activator protein‐1 activation , 2002, Molecular carcinogenesis.

[51]  Peter Angel,et al.  The jun proto-oncogene is positively autoregulated by its product, Jun/AP-1 , 1988, Cell.

[52]  Qiang Shen,et al.  The AP-1 transcription factor regulates postnatal mammary gland development. , 2006, Developmental biology.

[53]  P. Steinert,et al.  Loricrin Expression in Cultured Human Keratinocytes Is Controlled by a Complex Interplay between Transcription Factors of the Sp1, CREB, AP1, and AP2 Families* , 2002, The Journal of Biological Chemistry.

[54]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[55]  R. Eckert,et al.  Transcription factor regulation of epidermal keratinocyte gene expression , 2004, Molecular Biology Reports.

[56]  R. Isseroff,et al.  Epidermal growth factor (EGF)‐mediated DNA‐binding activity of AP‐1 is attenuated in senescent human epidermal keratinocytes , 2005, Experimental dermatology.

[57]  R. Eckert,et al.  Involucrin expression in the corneal epithelium: an essential role for Sp1 transcription factors. , 2005, Investigative ophthalmology & visual science.

[58]  M. Karin,et al.  AP-1 in cell proliferation and survival , 2001, Oncogene.

[59]  Marshall W. Anderson,et al.  A Dominant-Negative c-jun Mutant Inhibits Lung Carcinogenesis in Mice , 2010, Cancer Prevention Research.

[60]  T. Zaim,et al.  The distal regulatory region of the human involucrin promoter is required for expression in epidermis. , 1998, The Journal of biological chemistry.

[61]  R. Eckert,et al.  Regulation of involucrin gene expression. , 2004, The Journal of investigative dermatology.

[62]  B. Spiegelman,et al.  c-fos is required for malignant progression of skin tumors , 1995, Cell.

[63]  R. Eckert,et al.  p38 Mitogen-Activated Protein Kinases on the Body Surface – A Function for p38δ , 2003 .

[64]  C. Remé,et al.  Fra-1 replaces c-Fos-dependent functions in mice. , 2000, Genes & development.

[65]  R. Eckert,et al.  The distal and proximal regulatory regions of the involucrin gene promoter have distinct functions and are required for in vivo involucrin expression. , 2006, The Journal of investigative dermatology.